For health care professionals in EUROPE except those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
About the mCRM™ System
Modular therapy represents a paradigm shifting in treating CRM patients. The Boston Scientific Modular CRM System consists of the extrathoracically-positioned EMBLEM S-ICD and EMPOWER Leadless Pacemaker that are designed to work together to co-ordinate treatment. Providing individualised, tailored therapy, as and when the patient needs it, while avoiding more invasive approaches.
>75%
of VR ICD patients have no pacing indication at implant1,2
∽2%
of ICD patients develop a pacing need each year3
1. When the EMBLEM S-ICD senses an episode of tachycardia, it triggers the EMPOWER Leadless Pacemaker to provide ATP therapy, which may stop the tachycardia and reset the heart to a normal rhythm.
2. The EMBLEM S-ICD continuously monitors for the result of the ATP therapy.
a. If the ATP successfully terminated the tachycardia and returned the heart to a normal rhythm, the EMBLEM S-ICD will continue monitoring and no shock will be delivered.
b. If the ATP did not terminate the tachycardia, the EMBLEM S-ICD will deliver shock therapy.
Tjong FVY, et al. HRS 2016.
Watch the system in action as the EMBLEM™ S-ICD and EMPOWER™ LP coordinate during an mCRM™ therapy sequence.
*EMPOWER™ component pending CE Mark. Not available for sale.
References:
1. Gasparini, M, Lunati, MG, Proclemer, A, et al. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality. JACC Clin Electrophysiol. 2017;3(11):1275–1282.
2. Data on VR devices from LATITUDE Boston Scientific data on file.
3. Botto GL, Forleo GB, Capucci A, , et al. The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not? Europace. 2017;19(11):1826–1832.
4. Boston Scientific. Data on file.
ATP, antitachycardia pacing; CRM, cardiac rhythm management; ICD, implantable cardioverter defibrillator; LP, leadless pacemaker; MVT, monomorphic ventricular tachycardia; S-ICD, subcutaneous ICD.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
